CHARACTERISTICS AND PROGNOSIS OF HORMONE RECEPTOR POSITIVE AND HER2 NEGATIVE RECURRENT BREAST CANCER PATIENTS RECEIVING POSTOPERATIVE AROMATASE INHIBITOR

被引：0
|
作者：
Mayumi, Ishida [1 ]
Akiko, Igawa [1 ]
Akihiro, Saruwatari [1 ]
Masahiro, Oikawa [1 ]
Chinami, Koga [1 ]
Sumiko, Nishimura [1 ]
Yumiko, Koi [1 ]
Sayuri, Akiyoshi [1 ]
Yoshiaki, Nakamura [1 ]
Shinji, Ohno [1 ]
机构：
[1] Kyushu Natl Canc Ctr, Fukuoka, Japan
来源：
BREAST | 2013年 / 22卷
关键词：
D O I：
10.1016/S0960-9776(13)70098-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S48 / S49
页数：2
相关论文
共 50 条
  • [21] Tamoxifen resistance: EGFR expression in hormone receptor-positive and HER2 negative breast cancer
    Bae, S. Y.
    Nam, S. J.
    Lee, S. K.
    Kim, S. W.
    Lee, J. E.
    Yu, J. H.
    CANCER RESEARCH, 2017, 77
  • [22] Hormone Receptor Positive/HER2 Negative Breast Cancer With Isolated Bladder Metastasis: A Rare Case
    Khan, Noman Ahmed Jang
    Abdallah, Mahmoud
    Tirona, Maria Tria
    JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS, 2021, 9
  • [23] Concordance of HER2 and hormone receptor expression in primary and recurrent breast cancer
    Wirk, B
    Geiger, X
    Hillman, D
    Perez, EA
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S89 - S89
  • [24] DOES ADJUVANT CHEMOTHERAPY BENEFIT PATIENTS WITH NODE-POSITIVE, HORMONE-RECEPTOR POSITIVE, AND HER2 NEGATIVE BREAST CANCER?
    Harano, K.
    Hashimoto, K.
    Shimizu, C.
    Hirata, T.
    Yonemori, K.
    Tamura, K.
    Katsumata, N.
    Ando, M.
    Fujiwara, Y.
    ANNALS OF ONCOLOGY, 2010, 21 : 90 - 91
  • [25] Impact of hormonal receptor status on prognosis in HER2 positive breast cancer
    Cantini, L.
    Pistelli, M.
    Paesani, M.
    Ballatore, Z.
    Bastianelli, L.
    De Lisa, M. G.
    Santoni, M.
    Pagliacci, A.
    Battelli, N.
    Bracci, R.
    Maccaroni, E.
    Valeri, I.
    Biscotti, T.
    Santinelli, A.
    Berardi, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [26] IMPACT OF HORMONE RECEPTOR STATUS AND HER2 ON SURVIVAL OF TRIPLE NEGATIVE BREAST CANCER PATIENTS
    Xiao, H.
    Tan, F.
    Huang, Y.
    Feldman, J.
    Koniaris, L.
    Gummadi, S.
    Adunlin, G. B.
    Ali, A. A.
    VALUE IN HEALTH, 2013, 16 (03) : A131 - A131
  • [27] Immune environment of high-TIL breast cancer: triple negative and hormone receptor positive HER2 negative
    Shin, Su-Jin
    Park, Inho
    Go, Heounjeong
    Ko, Jiwon
    Lee, Yangkyu
    Kim, Jee Hung
    Ahn, Sung Gwe
    Jeong, Joon
    Bae, Soong June
    Cha, Yoon Jin
    NPJ BREAST CANCER, 2024, 10 (01)
  • [28] HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
    Qin, Tao
    Yuan, Zhongyu
    Peng, Roujun
    Bai, Bing
    Shi, Yanxia
    Teng, Xiaoyu
    Liu, Donggeng
    Wang, Shusen
    ONCOTARGETS AND THERAPY, 2013, 6 : 341 - 347
  • [29] Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2
    Doss, Sally
    Robertson, Janet
    Adam, Jane
    LANCET ONCOLOGY, 2012, 13 (08): : 766 - 767
  • [30] Podoplanin expression in cancer-associated fibroblasts predicts unfavorable prognosis in node-negative breast cancer patients with hormone receptor-positive/HER2 − negative subtype
    Yuko Tanaka
    Takashi Ohno
    Taichi Kadonaga
    Yoshiteru Kidokoro
    Makoto Wakahara
    Kanae Nosaka
    Tomohiko Sakabe
    Yoshimasa Suzuki
    Hiroshige Nakamura
    Yoshihisa Umekita
    Breast Cancer, 2021, 28 : 822 - 828
12345